Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | UNG | P13051 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | HPN | P05981 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209838 | 0.84 | GLS (0.52) | NAMPTHDAC1HDAC6HDAC10L3MBTL1 | |
| SCHEMBL29952891 | 0.84 | GLS (0.52) | NAMPTHDAC1HDAC6HDAC10L3MBTL1 | |
| SCHEMBL26508626 | 0.83 | HDAC1 (0.56) | NAMPTHDAC1EPHX2NR1H4L3MBTL1 | |
| SCHEMBL208544 | 0.81 | EPHX2 (0.57) | NAMPTHDAC1EPHX2NR1H4L3MBTL1 | |
| SCHEMBL80280 | 0.81 | NAMPT (0.47) | NAMPTHDAC1PPARGPPARAPPARD | |
| SCHEMBL6258024 | 0.80 | HDAC1 (0.53) | HDAC1L3MBTL1GLS | |
| SCHEMBL23782567 | 0.78 | UNG (0.44) | L3MBTL1UNG | |
| SCHEMBL3180689 | 0.76 | L3MBTL1 (0.61) | NAMPTHDAC1HDAC6HDAC10L3MBTL1 | |
| SCHEMBL12133585 | 0.76 | HDAC1 (0.58) | NAMPTHDAC1PPARGPPARAPPARD | |
| SCHEMBL22452275 | 0.76 | PPARG (0.52) | NAMPTHDAC1PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129527-B2 | cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers | NEREUS PHARMACUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129527-B2 | cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers | NEREUS PHARMACUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | BEYONDSPRING PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | BEYONDSPRING PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | HPGDS, DHPS, HCCS | NAMPT 562/4885HDAC1 2200/4885EPHX2 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.